Scrip is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Athira Pharma, Inc.

Latest From Athira Pharma, Inc.

Defender’s Scopolamine Nasal Gel Secures Pivotal Win In Motion Sickness

The US firm’s nasal gel formulation of the anticholinergic compound has succeeded in a second Phase III trial, bringing Defender closer to entering a market dominated by Bayer’s Transderm Scop.

Clinical Trials Ingredients

Athira's Alzheimer's Drug Passes Futility Analysis; Data Targeted For 2024

An unblinded interim efficacy analysis by a DMC recommended a Phase II/III study testing fosgonimeton in Alzheimer's patients should continue.

Clinical Trials Neurology

Rising Tide Lifts Many Ships In Wake Of Eisai/Biogen’s Lecanemab Readout

Eisai and Biogen had double-digit stock price gains based on the positive Phase III readout for lecanemab. The good news also lifted competitors Lilly and Roche as well as earlier-stage Alzheimer’s drug developers.

Clinical Trials Neurology

Athira Says Phase II Alzheimer’s Miss Will Inform Ongoing Phase III Study

Athira hoped a small Phase II study would show a benefit on working memory processing speed, but it missed its primary and all secondary endpoints, reducing confidence in the Phase III program.

Clinical Trials Business Strategies
See All

Company Information

  • Industry
  • Pharmaceuticals
  • Biotechnology
    • Drug Discovery Tools
  • Other Names / Subsidiaries
    • M3 M3 Biotechnology, Inc.